Living with moderate to severe plaque psoriasis can be a daily struggle, affecting both physical comfort and emotional well-being. New research compared four specific types of treatments called IL-23 and IL-17 inhibitors. These are medications designed to calm the immune system's overreaction in the skin.
The study looked at 27 clinical trials to see how these drugs performed. For clearing skin, Guselkumab, Secukinumab, and Brodalumab ranked highly. When looking specifically at patients who achieved clear or almost cleared skin and improved quality of life scores, Tildrakizumab showed high performance.
While the results are promising, some details are still fuzzy. Because different trials reported side effects in different ways, it is hard to say exactly how safe each drug is compared to the others. These findings help doctors choose a specific plan based on what works best for a patient's skin and lifestyle.
Common questions
Which medications were most effective at clearing skin?
The study found that Guselkumab (200 mg), Secukinumab (300 mg), and Brodalumab (210 mg) ranked highly for achieving PASI 75 and PASI 90, which are measures of how much skin clears up. Tildrakizumab at both 100 mg and 200 mg also showed high performance in helping patients achieve clear or almost cleared skin.
Are these treatments safe for people with psoriasis?
The study noted some side effects, such as Brodalumab 140 mg and Secukinumab 150 mg. However, because different trials reported safety data in different ways, the results are not uniform. You should talk to your doctor to understand the specific risks and benefits of each medication for your personal health.
How does Tildrakizumab compare to other options?
Tildrakizumab at 100 mg and 200 mg showed high values for clearing skin and improving Dermatology Life Quality Index scores. This means it performed well in helping patients feel better and have clearer skin compared to some other treatments in the study.
